Fig. 2

Progression-free survival (PFS) for pembrolizumab with or without chemotherapy. Kaplan–Meier curves illustrating the PFS of patients with large-cell carcinoma (LCC) (A, C) or large-cell neuroendocrine carcinoma (LCNEC) (B, D) who received pembrolizumab with chemotherapy as first-line therapy (A-B) or pembrolizumab with or without chemotherapy as second-line or later-line therapy (C-D). The dashed lines correspond to the 95% lower and upper confidence intervals. Tick marks indicate the number of censored cases per time point. The risk table below shows the number of cases per time point